Sanofi's Dupixent Emerges as First Biologic Treatment for COPD in China, Pioneering a New Era in Respiratory Medicine
Sep 28, 2024
Sanofi Equities
Dupixent® (dupilumab) Becomes China's First Biologic for COPD through Regeneron Pharmaceuticals
Sep 28, 2024
In-Depth Analysis of Noteworthy Stocks: Meta, Sanofi, and CME Group
Aug 15, 2024
Sanofi's Dupixent Secures EU Approval as Novel COPD Therapy
Jul 4, 2024